CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has entered into a collaboration agreement with the Nipro Corporation’s pharmaceutical division to develop technology to support commercial implementation of the INTERCEPT System for Red Blood Cells (RBCs). Under the agreement, the companies will leverage Nipro’s proprietary technology to develop a set that enables the mixing and delivery of key chemical compounds to the red cell component, a process which is integral to the pathogen inactivation technology for RBCs.
Help employers find you! Check out all the jobs and post your resume.
